Full Text
EE387 Economic Evaluation of Tarlatamab as Second-Line Therapy for Metastatic Small-Cell Lung Cancer: A United States Perspective

Abstract

Authors

Hanrui Zheng Bin Wu MING HU

Back to Volume 28, Supplemental Issue 12S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×